Bryan Witherbee, CEO of Adarza Biosystems discusses ZIVA™, a label-free protein detection platform that can accurately test 100s of protein from a single drop of blood in a time and cost-efficient manner. While the initial launch of ZIVA was focused on biomarker detection in cancer, they have changed direction to assist in vaccine development and immunosurveillance following COVID-19 and they are now applying this technology in the quantification of SARS-CoV-2/COVID-19 antibodies and other upper respiratory pathogens.
Bryan Witherbee, President, Adarza BioSystems. Bryan joined Adarza BioSystems in January of 2017 to provide leadership as Adarza transitions from a technology developer to a commercial technology provider. Bryan’s career has spanned scientific, business development, and senior leadership positions in large research institutions and early-stage startups in pharma, ag biotech, and life science technologies. He brings many years of experience with a successful track record in developing and commercializing new technologies. Bryan’s career started at Sigma Diagnostics where he developed and commercialized clinical immunoassays and coagulation reagents. Over the next 20 years, he held various R&D leadership roles at Monsanto and Pfizer. He most recently served as Scientific Leader within the Genomics Division at Becton Dickinson (BD) where he provided leadership for the successful commercial launch of solutions for NextGen Sequencing and single cell genomics. Prior to that, he was CSO at GenCell Biosystems, which was acquired by BD in 2014. His key accomplishments include identification and implementation of microfluidic technologies for molecular biology applications, frozen cell technologies, and various high throughput multiplexing technologies for systems biology. Bryan has a BS in Biochemistry from Truman State University.